Cargando…

Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial

A few studies suggested high stereo-specifically numbered (sn)-2 palmitate in a formula might favor the gut Bifidobacteria of infants. The initial colonization and subsequent development of gut microbiota in early life might be associated with development and later life functions of the central nerv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wei, Zhao, Ai, Liu, Biao, Ye, Wen-Hui, Su, Hong-Wen, Li, Jing, Zhang, Yu-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926808/
https://www.ncbi.nlm.nih.gov/pubmed/33671493
http://dx.doi.org/10.3390/nu13020693
_version_ 1783659547283423232
author Wu, Wei
Zhao, Ai
Liu, Biao
Ye, Wen-Hui
Su, Hong-Wen
Li, Jing
Zhang, Yu-Mei
author_facet Wu, Wei
Zhao, Ai
Liu, Biao
Ye, Wen-Hui
Su, Hong-Wen
Li, Jing
Zhang, Yu-Mei
author_sort Wu, Wei
collection PubMed
description A few studies suggested high stereo-specifically numbered (sn)-2 palmitate in a formula might favor the gut Bifidobacteria of infants. The initial colonization and subsequent development of gut microbiota in early life might be associated with development and later life functions of the central nervous system via the microbiota–gut–brain axis, such as children with autism. This study aims to assess the hypothesized effect of increasing the amount of palmitic acid esterified in the sn-2 position in infant formula on neurodevelopment in healthy full-term infants and to explore the association of this effect with the altered gut Bifidobacteria. One hundred and ninety-nine infants were enrolled in this cluster randomized clinical trial: 66 breast-fed (BF group) and 133 formula-fed infants who were clustered and randomly assigned to receive formula containing high sn-2 palmitate (sn-2 group, n = 66) or low sn-2 palmitate (control group, n = 67), where 46.3% and 10.3% of the palmitic acid (PA) was sn-2-palmitate, respectively. Infants’ neurodevelopmental outcomes were measured by the Ages and Stages Questionnaire, third edition (ASQ-3). Stool samples were collected for the analysis of Bifidobacteria (Trial registration number: ChiCTR1800014479). At week 16, the risk of scoring close to the threshold for fine motor skills (reference: scoring above the typical development threshold) was significantly lower in the sn-2 group than the control group after adjustment for the maternal education level (p = 0.036) but did not differ significantly versus the BF group (p = 0.513). At week 16 and week 24, the sn-2 group (week 16: 15.7% and week 24: 15.6%) had a significantly higher relative abundance of fecal Bifidobacteria than the control group (week 16: 6.6%, p = 0.001 and week 24:11.2%, p = 0.028) and did not differ from the BF group (week 16: 14.4%, p = 0.674 and week 24: 14.9%, p = 0.749). At week 16, a higher relative abundance of Bifidobacteria was associated with the decreased odds of only one domain scoring close to the threshold in the formula-fed infants group (odds ratio (OR), 95% confidence interval (CI): 0.947 (0.901–0.996)). Elevating the sn-2 palmitate level in the formula improved infants’ development of fine motor skills, and the beneficial effects of high sn-2 palmitate on infant neurodevelopment was associated with the increased gut Bifidobacteria level.
format Online
Article
Text
id pubmed-7926808
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79268082021-03-04 Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial Wu, Wei Zhao, Ai Liu, Biao Ye, Wen-Hui Su, Hong-Wen Li, Jing Zhang, Yu-Mei Nutrients Article A few studies suggested high stereo-specifically numbered (sn)-2 palmitate in a formula might favor the gut Bifidobacteria of infants. The initial colonization and subsequent development of gut microbiota in early life might be associated with development and later life functions of the central nervous system via the microbiota–gut–brain axis, such as children with autism. This study aims to assess the hypothesized effect of increasing the amount of palmitic acid esterified in the sn-2 position in infant formula on neurodevelopment in healthy full-term infants and to explore the association of this effect with the altered gut Bifidobacteria. One hundred and ninety-nine infants were enrolled in this cluster randomized clinical trial: 66 breast-fed (BF group) and 133 formula-fed infants who were clustered and randomly assigned to receive formula containing high sn-2 palmitate (sn-2 group, n = 66) or low sn-2 palmitate (control group, n = 67), where 46.3% and 10.3% of the palmitic acid (PA) was sn-2-palmitate, respectively. Infants’ neurodevelopmental outcomes were measured by the Ages and Stages Questionnaire, third edition (ASQ-3). Stool samples were collected for the analysis of Bifidobacteria (Trial registration number: ChiCTR1800014479). At week 16, the risk of scoring close to the threshold for fine motor skills (reference: scoring above the typical development threshold) was significantly lower in the sn-2 group than the control group after adjustment for the maternal education level (p = 0.036) but did not differ significantly versus the BF group (p = 0.513). At week 16 and week 24, the sn-2 group (week 16: 15.7% and week 24: 15.6%) had a significantly higher relative abundance of fecal Bifidobacteria than the control group (week 16: 6.6%, p = 0.001 and week 24:11.2%, p = 0.028) and did not differ from the BF group (week 16: 14.4%, p = 0.674 and week 24: 14.9%, p = 0.749). At week 16, a higher relative abundance of Bifidobacteria was associated with the decreased odds of only one domain scoring close to the threshold in the formula-fed infants group (odds ratio (OR), 95% confidence interval (CI): 0.947 (0.901–0.996)). Elevating the sn-2 palmitate level in the formula improved infants’ development of fine motor skills, and the beneficial effects of high sn-2 palmitate on infant neurodevelopment was associated with the increased gut Bifidobacteria level. MDPI 2021-02-22 /pmc/articles/PMC7926808/ /pubmed/33671493 http://dx.doi.org/10.3390/nu13020693 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Wei
Zhao, Ai
Liu, Biao
Ye, Wen-Hui
Su, Hong-Wen
Li, Jing
Zhang, Yu-Mei
Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial
title Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial
title_full Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial
title_fullStr Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial
title_full_unstemmed Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial
title_short Neurodevelopmental Outcomes and Gut Bifidobacteria in Term Infants Fed an Infant Formula Containing High sn-2 Palmitate: A Cluster Randomized Clinical Trial
title_sort neurodevelopmental outcomes and gut bifidobacteria in term infants fed an infant formula containing high sn-2 palmitate: a cluster randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926808/
https://www.ncbi.nlm.nih.gov/pubmed/33671493
http://dx.doi.org/10.3390/nu13020693
work_keys_str_mv AT wuwei neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial
AT zhaoai neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial
AT liubiao neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial
AT yewenhui neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial
AT suhongwen neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial
AT lijing neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial
AT zhangyumei neurodevelopmentaloutcomesandgutbifidobacteriainterminfantsfedaninfantformulacontaininghighsn2palmitateaclusterrandomizedclinicaltrial